Pathophysiology of Bisphosphonates-associated Osteonecrosis of the Jaw (R21)
The summary for the Pathophysiology of Bisphosphonates-associated Osteonecrosis of the Jaw (R21) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Pathophysiology of Bisphosphonates-associated Osteonecrosis of the Jaw (R21): -The National Institute of Dental and Craniofacial Research (NIDCR), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), and the National Cancer Institute (NCI) invite Exploratory/Developmental (R21) grant applications for research projects focusing on basic and translational studies of osteonecrosis of the jaw (ONJ), an oral complication associated with bisphosphonate use. Projects should aim to identify and characterize the pathophysiological mechanisms that lead to impaired bone healing and the development of ONJ. -This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism and runs in parallel with two FOAs of identical scientific scope, PA-06-500 that solicits applications under the NIH Individual Research Project Grant (R01) mechanism, and PA-06-502 that solicits applications under the NIH Small Research Grant (R03) mechanism. -Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.
|Federal Grant Title:||Pathophysiology of Bisphosphonates-associated Osteonecrosis of the Jaw (R21)|
|Federal Agency Name:||National Institutes of Health|
|Grant Categories:||Health Education|
|Type of Opportunity:||Discretionary|
|Funding Opportunity Number:||PA-06-501|
|Type of Funding:||Grant|
|CFDA Descriptions:||Oral Diseases and Disorders Research 93.395 Cancer Treatment Research|
|Current Application Deadline:||No deadline provided|
|Original Application Deadline:||Multiple Receipt Dates - See Link to Full Announce|
|Posted Date:||Jul 31, 2006|
|Creation Date:||Oct 02, 2007|
|Archive Date:||Dec 05, 2008|
|Total Program Funding:|
|Maximum Federal Grant Award:||$200,000|
|Minimum Federal Grant Award:|
|Expected Number of Awards:|
|Cost Sharing or Matching:||93.846 -- Arthritis, Musculoskeletal and Skin Diseases Research|
- Applicants Eligible for this Grant
- Special district governments County governments Private institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled "Additional Information on Eligibility" for clarification) Native American tribal governments (Federally recognized) City or township governments Small businesses State governments For profit organizations other than small businesses Independent school districts Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Additional Information on Eligibility
- Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply. Faith-based or community-based organizations can apply. Applicants may submit more than one application, provided each application is scientifically distinct. Projects must focus on studying oral bone homeostasis, healing response or repair capacity in the presence or absence of bisphosphonates rather than on the broad effects of bisphosphonates on bone quality. Projects that examine the effects of bisphosphonates on skeletal biology will not be considered unless the experimental design includes analysis of oral bones. Projects may study the effects of bisphosphonates on other physiological processes such as angiogenesis but only within the context that perturbation of these processes may compromise oral bone homeostasis and healing. Projects that examine the pharmacology of bisphosphonates will be considered non-responsive unless the projects propose to test whether genetic variations alter the pharmacokinetics or pharmacodynamics of bisphosphonates. Epidemiological studies are non-responsive.
- Link to Full Grant Announcement
- Information not provided
- Grant Announcement Contact
- NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
- More Grants from the National Institutes of Health
- • Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Administrative Resource...
- • Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Research Resource (U24)...
- • New Cohorts for Environmental Exposures and Cancer Risk (CEECR; UG3/UH3 Clinical Trial Not...
- • Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical ...
- • Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Tria...